Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (Weighted Average) (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $115.6 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 2.95% year-over-year to $115.6 million; the TTM value through Mar 2026 reached $115.6 million, up 2.95%, while the annual FY2025 figure was $112.7 million, 3.33% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $115.6 million in Q1 2026 for Viking Therapeutics, up from $112.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $115.6 million in Q1 2026 and bottomed at $76.7 million in Q3 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $97.8 million, with a median of $103.6 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) fell 1.69% in 2022 and then soared 32.28% in 2024.
  • Viking Therapeutics' Shares Outstanding (Weighted Average) stood at $77.0 million in 2022, then rose by 22.5% to $94.3 million in 2023, then rose by 15.57% to $109.0 million in 2024, then increased by 3.33% to $112.7 million in 2025, then grew by 2.57% to $115.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $115.6 million, $112.7 million, and $112.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.